Skip to main content
Equibles
AVTX logo

AVTX · Avalo Therapeutics, Inc.

Track AVTX — free

Use AVTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$19.23 +0.23 (+1.21%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$1.03B
Shares
53.63M

AVTX metrics

57 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$19.23
Market cap
$1.03B

Price action

19 metrics
Price change (1W)
-1.8%
Price change (30D)
-2.7%
Price change (3M)
+46.8%
Price change (6M)
+11.1%
Price change (YTD)
+5.9%
Price change (1Y)
+89.3%
Trailing year
Price change (5Y)
—
52-week high
$22.87
52-week low
$9.76
Change from 52-week high
-15.9%
Change from 52-week low
+97.0%
Annualized volatility
86.7%
Beta
1.2
RSI (14D)
49.4
Price vs SMA 50
+0.7%
Price vs SMA 200
+13.7%
Avg volume (3M)
1.24M
Relative volume
0.5
Average dollar volume
$22.01M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
53.63M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
5,371.4×
reciprocal yield 0.0%
P / book
2.3
reciprocal yield 43.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-9.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-123,601.7%
Trailing 12 months
Net margin
-132,642.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$91.36M
Net income (TTM)
−$100.33M
Trailing 12 months
Diluted EPS (TTM)
$-4.48
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-116,715.19

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$192,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+302.6%
Year over year · more shares
Revenue CAGR (3Y)
-85.2%
Revenue CAGR (5Y)
-61.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-22.4%
Return on assets
-20.4%
Debt / equity
—
Current ratio
19.3
EBITDA (TTM)
−$91.25M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$85.38M
Total assets
$490.78M
Total debt
$15.30M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$68.29M
Capital expenditures (TTM)
$95,000
R&D (TTM)
$64.35M
SG&A (TTM)
$10.30M
Stock compensation (TTM)
$16.54M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
128
13F filer change QoQ
+27
Institutional ownership
133.6%

Short interest

3 metrics
Short interest
24.4%
Latest settlement · 20.2 days to cover
Days to cover
20.2d
Short-squeeze score
77 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.69M
Insider-sentiment score
54 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1534120 CUSIP 05338F306 13F (30d) 101 filings 101 filers Visit website Investor relations